JavaScript seem to be disabled in your browser.
You must have JavaScript enabled in your browser to utilize the functionality of this website.
Gevokizumab is an investigational antibody with allosteric modulating properties. Gevokizumab binds to interleukin-1 beta, a pro-inflammatory cytokine, and downmodulates the cellular signaling events that produce inflammation. IL-1 beta has been implicated in cardiovascular conditions, lung cancer, and auto-inflammatory diseases.